Retrospective Investigation of Testosterone Undecanoate Depot for the Long-term Treatment of Male Hypogonadism in Clinical Practice
Version of Record online: 27 NOV 2013
© 2013 International Society for Sexual Medicine
The Journal of Sexual Medicine
Volume 11, Issue 2, pages 574–582, February 2014
How to Cite
Conaglen, H. M., Paul, R. G., Yarndley, T., Kamp, J. , Elston, M. S. and Conaglen, J. V. (2014), Retrospective Investigation of Testosterone Undecanoate Depot for the Long-term Treatment of Male Hypogonadism in Clinical Practice. Journal of Sexual Medicine, 11: 574–582. doi: 10.1111/jsm.12401
- Issue online: 27 JAN 2014
- Version of Record online: 27 NOV 2013
- Waikato Clinical School Summer Studentship
- Testosterone Replacement;
- Testosterone Undecanoate Depot;
- Testosterone Deficiency Syndrome
Testosterone undecanoate depot (TUD) administered intramuscularly is an effective form of testosterone replacement therapy (TRT) for male hypogonadism. Because of the ease of administration, TUD therapy may be preferable to subcutaneously implanted extended release T pellet implants (TI).
The primary objective was to retrospectively assess the efficacy and safety of long-term (≥2 years therapy) TUD therapy in the clinical setting. The secondary objective was to retrospectively compare TUD with TI therapy.
Retrospective data were collected from the Waikato Hospital Endocrine Database for 179 hypogonadal men treated with TUD for ≥2 years from 1998–2011, with 124 of these men receiving previous TI therapy.
Main Outcome Measures
The main outcome measure for efficacy was serum trough total testosterone (TT), and for safety an increase in hemoglobin (Hb) and/or hematocrit (Hct), rise in prostate-specific antigen (PSA) and/or prostatic biopsy and alteration in body mass index and lipid profile. Additional outcome measures were changes in the dosing and/or interval regimens for TUD therapy.
Overall, 72% of trough TT levels were in the normal range for TUD therapy compared with 53% of trough TT levels during TI therapy. TUD therapy was well tolerated with 162 men (90.5%) completing 2 years of treatment, and only seven men (3.9%) stopping TUD because of adverse effects. A rise in Hb and/or Hct occurred in 25 men (14%), and a significant rise in PSA in 20 men (13%) at some stage during TUD therapy. At 2 years, 91% of men received the standard 1,000 mg TUD dose with 66% at the standard dosing interval of 10–14 weekly.
TUD is an efficacious, safe, and well tolerated form of TRT, and individual optimisation of the dose and/or interval is only required in the minority of men. Particularly given the ease of administration, TUD was the preferred TRT for both patients and clinicians. Conaglen HM, Paul RG, Yarndley T, Kamp J, Elston MS, and Conaglen JV. Retrospective investigation of testosterone undecanoate depot for the long-term treatment of male hypogonadism in clinical practice. J Sex Med 2014;11:574–582.